title: An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver.
abstract: Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.
authors.affiliation: Liver Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico.
authors.forename: Norberto C
authors.initials: NC
authors.lastname: Chávez-Tapia
authors.forename: Ezequiel
authors.initials: E
authors.lastname: Ridruejo
authors.forename: Angelo
authors.initials: A
authors.lastname: Alves de Mattos
authors.forename: Fernando
authors.initials: F
authors.lastname: Bessone
authors.forename: Jorge
authors.initials: J
authors.lastname: Daruich
authors.forename: Juan F
authors.initials: JF
authors.lastname: Sánchez-Ávila
authors.forename: Hugo
authors.initials: H
authors.lastname: Cheinquer
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Zapata
authors.forename: Misael
authors.initials: M
authors.lastname: Uribe
authors.forename: Francisco
authors.initials: F
authors.lastname: Bosques-Padilla
authors.forename: Adrián
authors.initials: A
authors.lastname: Gadano
authors.forename: Alejandro
authors.initials: A
authors.lastname: Sosa
authors.forename: Milagros
authors.initials: M
authors.lastname: Dávalos-Moscol
authors.forename: Claudio
authors.initials: C
authors.lastname: Marroni
authors.forename: Linda
authors.initials: L
authors.lastname: Muñoz-Espinoza
authors.forename: Graciela
authors.initials: G
authors.lastname: Castro-Narro
authors.forename: Raymundo
authors.initials: R
authors.lastname: Paraná
authors.forename: Nahum
authors.initials: N
authors.lastname: Méndez-Sánchez
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005820:Genetic Testing; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*; D019562:Viral Load; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D009842:Oligopeptides; D011092:Polyethylene Glycols; D011392:Proline; D011480:Protease Inhibitors; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide